The abstract explicitly states that biomarkers definitively identifying specific pathological entities in sporadic FTLD have been elusive, which has impeded treatment development. This represents a critical diagnostic gap that limits precision medicine approaches for FTLD patients. Gap type: open_question Source paper: Frontotemporal lobar degeneration. (None, None, PMID:37563165)
Landscape Summary: Why have biomarkers for distinguishing FTLD pathological subtypes in sporadic disease remained elusive? is a 0.82 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why have biomarkers for distinguishing FTLD pathological subtypes in sporadic disease remained elusive? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: